Bank of America Reiterates "Neutral" Rating for Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report)'s stock had its "neutral" rating restated by equities researchers at Bank of America in a research note issued to investors on Monday, MarketBeat Ratings reports.

Several other equities research analysts have also recently issued reports on the stock. Wells Fargo & Company decreased their price target on shares of Sarepta Therapeutics from $115.00 to $100.00 and set an "overweight" rating on the stock in a research note on Thursday, May 8th. Morgan Stanley cut their price target on Sarepta Therapeutics from $182.00 to $113.00 and set an "overweight" rating for the company in a report on Wednesday, May 7th. Guggenheim cut their price target on shares of Sarepta Therapeutics from $112.00 to $98.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. UBS Group lowered their price target on Sarepta Therapeutics from $188.00 to $85.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. Finally, Deutsche Bank Aktiengesellschaft reduced their price objective on Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating on the stock in a research note on Wednesday, March 19th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $115.48.

Sarepta Therapeutics Price Performance

Shares of SRPT traded down $17.29 on Monday, reaching $18.89. The stock had a trading volume of 20,878,842 shares, compared to its average volume of 1,891,180. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The firm has a market capitalization of $1.86 billion, a PE ratio of 15.21 and a beta of 0.61. Sarepta Therapeutics has a twelve month low of $18.33 and a twelve month high of $173.25. The firm has a 50-day moving average of $46.25 and a 200 day moving average of $86.03.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing the consensus estimate of $2.20 by ($5.62). Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. The business had revenue of $744.86 million during the quarter, compared to analyst estimates of $685.75 million. During the same quarter in the prior year, the company earned $0.73 earnings per share. The firm's revenue for the quarter was up 80.2% compared to the same quarter last year. Sell-side analysts expect that Sarepta Therapeutics will post 2.67 EPS for the current year.

Institutional Trading of Sarepta Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Manchester Capital Management LLC boosted its holdings in Sarepta Therapeutics by 86.6% in the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock worth $29,000 after purchasing an additional 110 shares during the period. Byrne Asset Management LLC bought a new position in shares of Sarepta Therapeutics during the first quarter valued at approximately $30,000. Center for Financial Planning Inc. acquired a new stake in shares of Sarepta Therapeutics during the 1st quarter worth approximately $31,000. Ancora Advisors LLC boosted its position in Sarepta Therapeutics by 150.0% during the 1st quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company's stock valued at $32,000 after purchasing an additional 300 shares during the period. Finally, Steward Partners Investment Advisory LLC increased its position in Sarepta Therapeutics by 164.4% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company's stock worth $38,000 after buying an additional 194 shares during the period. 86.68% of the stock is owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.